Duality Biotherapeutics, Inc.
public_traded
Duality Biotherapeutics, Inc. is publicly traded on HKSE under ticker 9606.HK.
Duality Biotherapeutics, Inc. operates as a clinical stage company. It focuses on the development of next generation antibody-drug conjugate therapeutics and duality immune toxin antibody conjugate therapeutic. The company was founded by Zhu Zhong Yuan on July 3, 2019 and is headquartered in Shanghai, China.